Welcome to MerLion Pharmaceuticals

Welcome to MerLion Pharmaceuticals

There is an urgent need for new antibacterials to counter the alarming spread of multi-drug resistant infections. Bacterial infections lead to around 17 million deaths worldwide, showing little respect for age, gender or social status.

MerLion Pharmaceuticals is focusing on the development of finafloxacin; an atypical fluoroquinolone differentiated by an outstanding safety profile and enhanced activity in the acidified environments found in many infection sites (e.g. urine, abscesses, deep seated wounds, chronically infected tissues and stomach mucosa) and within the intracellular compartments of infected macrophages. The compound shows impressive activity against persister and biofilm populations associated with chronic or recurring infections.

Finafloxacin appears particularly well suited for treating severe infections in hospital settings, including complicated urinary tract, respiratory tract, skin and soft tissue, intra-abdominal and gastrointestinal infections. The compound shows high bioavailability and very rapid bactericidal activity in vitro and in vivo. In addition, due to the superior safety profile, the drug can also be administered in high doses. Consequently, finafloxacin offers the real possibility of significantly reduced treatment durations and concomitant shorter stays in hospital.

The superior activity of finafloxacin under acidic conditions has been demonstrated for a large number of bacterial species and it is particularly relevant for those pathogens with intermediate or borderline susceptibility profiles. It is expected that infections with such pathogens (which potentially lead to relapses or clinical failures when treated with conventional fluoroquinolones) can be treated successfully with finafloxacin.